Mr. Damien McCallion:

To reassure the Chairman regarding the HPV screening, the critical path is the provision of a provider. At the moment, we are at 9% in the Coombe. This cannot change overnight, as the Chairman described, so we must secure a provider from our tender. That is the critical path. As Dr. Doherty said, our plan is aiming to get that in this year. That would be the target, regardless of whether we can do it this year or early next year. In respect of us trying to set out dates, at the moment given the history of this with dates, we need to be sure of our ground before we publish a date. We can only be in that position when we have gone to the next stage of the tender and are sure we have a provider with which we can work. To illustrate the point, if it is a new provider, there could be quite a lag time for its IT systems to interconnect, so the programme is designed totally around technology. Some providers may be able to connect very quickly while others may have an extensive period to connect. We will not know that until we secure a provider. As I said earlier, securing a provider in this context is quite challenging for a variety of reasons. A very small market of providers provide this type of capacity into Europe.